[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fatigue-syndrome-chronic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fatigue-syndrome-chronic":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,75,98,131,162,193,233,260,286,310,338],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100366289","phase-2-testosterone-replacement-in-male-cancer-survivors-with-fatigue-and-low-testosterone-100366289",false,"NCT04049331","Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone","Improving Patient-Important Outcomes With Testosterone Replacement in Hypogonadal Men With a Prior History of Cancer","Inclusion Criteria:\n\n* Cancer survivors who have received chemotherapy and\u002For radiation therapy for their cancer and are now in remission for at least one year\n* Non-hormone-dependent cancer, including most solid tumors, lymphomas and leukemias\n* Age: 18-54 years\n* Serum testosterone, measured by mass spectrometry (gold standard method), of \\\u003C348 ng\u002Fdl and\u002For free testosterone \\\u003C70 pg\u002Fml. The lower limits of the normal range for total testosterone in healthy young men (age 19-40 years), is 348 ng\u002FdL and the lower limits of free testosterone is \\\u003C70 pg\u002Fml in the Framingham Heart Study sample97. Therefore, young symptomatic men with total testosterone \\\u003C348 ng\u002Fdl could be considered testosterone deficient. As sex hormone binding globulin levels may be elevated in some men with cancer (resulting in elevation in total testosterone level), some of these symptomatic men may still be hypogonadal despite having total testosterone above this cut-off limit. However; their free testosterone levels may still be below the lower limit of normal. Thus, we will also include men with free testosterone \\\u003C70 pg\u002FmL.\n* Self-reported fatigue. We have selected these symptoms because they are commonly reported in male cancer survivors. Fatigue will be defined as a score on Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale of \\\u003C40, which best divides cancer patients from the general population with 84% accuracy, and was used as the cut-off for the NIA-funded 50-million-dollar testosterone trial (The T-Trial).\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Men with hormone-dependent cancers (breast, prostate or adenocarcinoma of unknown origin)\n* Men with brain cancer (potential cognitive impairment)\n* Use of anabolic agents (testosterone, dehydroepiandrosterone, growth hormone) within the past 6 months\n* Appetite stimulating agents e.g. megestrol acetate within the past 6 months\n* Systemic glucocorticoids e.g. prednisone 20 mg daily or equivalent doses of other glucocorticoids for more than two weeks in the past 6 months\n* Baseline hematocrit \\>48%\n* PSA \\>4 ng\u002Fml in Caucasians; \\>3 ng\u002Fml in African-Americans\n* Men with 1st order relatives with a history of prostate cancer\n* Uncontrolled congestive heart failure\n* Severe untreated sleep apnea\n* Myocardial infarction, acute coronary syndrome, revascularization surgery, or stroke within 3 months\n\n  o Previous stroke with residual cognitive or functional deficits; Mini-Mental State Examination score \\\u003C24\n* Serum creatinine \\>2.5 mg\u002FdL; ALT 3x upper limit of normal\n* Poorly controlled diabetes as defined by hemoglobin A1c \\>8.5%; Body mass index (BMI) \\>45 kg\u002Fm2\n* Untreated unipolar depression (treated depression with medications or counseling will be allowed\n* Bipolar disorder or schizophrenia","MALE","18 Years","54 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The overall goal of this study is to evaluate the effect of a testosterone drug called Depo-Testosterone (or 'testosterone cypionate'), an FDA-approved drug for improving fatigue, sexual function, quality of life, body composition, muscle strength, and physical activity in young cancer survivors who report fatigue and have low testosterone. Main hypothesis is that Testosterone administration in young male cancer survivors who are in remission for at least 1 year, report cancer-related fatigue and have symptomatic testosterone deficiency will be associated with greater improvements in fatigue scores compared with placebo.",[27,28],"Hypogonadism, Male","Fatigue Syndrome, Chronic",[30,31,32],"testosterone","hypogonadism","cancer related fatigue","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":37},"2021-03-22",{"date":41,"type":21},"2027-01-30",{"name":43,"class":44},"Seattle Institute for Biomedical and Clinical Research","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100642418","photobiomodulation-for-chronic-pain-and-fatigue-in-hypermobile-ehlers-danlos-syndrome-pbm-sedh-01-100642418","NCT07637084","Photobiomodulation for Chronic Pain and Fatigue in Hypermobile Ehlers-Danlos Syndrome (PBM-SEDh-01)","Effect of MLS® Class IV Laser Photobiomodulation on Chronic Pain and Fatigue in Hypermobile Ehlers-Danlos Syndrome: A Prospective Observational Pilot Study in Private Medical Practice","PBM-SEDh-01","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Confirmed diagnosis of hypermobile Ehlers-Danlos Syndrome (hEDS) according to 2017 International Consortium criteria\n* Chronic pain ≥ 3 months, average VAS score ≥ 4\u002F10 over the preceding week\n* Stable analgesic treatment for ≥ 4 weeks (if any)\n* Follow-up at Centre Médical ISM, Boulogne-Billancourt\n* Informed and non-opposition signed\n\nExclusion Criteria:\n\n* Suspicious or malignant skin lesion on areas to be treated\n* Non-modifiable photosensitizing treatment\n* Pregnancy or breastfeeding\n* Photosensitive epilepsy\n* Acute articular inflammatory flare at inclusion date\n* Analgesic treatment modification within 4 weeks prior to inclusion\n* Simultaneous participation in another research protocol","ALL",{"count":56,"type":21},25,"10 Weeks","OBSERVATIONAL","This study evaluates the effect of photobiomodulation (PBM) therapy using a MLS® class IV laser on chronic pain and fatigue in patients with hypermobile Ehlers-Danlos Syndrome (hEDS). hEDS is a hereditary connective tissue disorder characterized by joint hypermobility, chronic pain, and debilitating fatigue, for which therapeutic options remain limited.\n\nParticipants will receive 10 PBM sessions over 5 weeks (2 sessions per week), using red and near-infrared light (808 nm continuous + 905 nm pulsed) applied to painful areas identified at baseline. Pain (Visual Analogue Scale), multidimensional fatigue (MFI-20), and quality of life (EQ-5D-5L) will be assessed at baseline (T0), end of treatment (week 5), and follow-up (week 10).\n\nThis is a pilot observational study - the first to document the effect of MLS® laser PBM in hEDS. No additional procedures beyond routine care are required.",[61,62,28],"Ehlers-Danlos Syndrome, Hypermobile","Chronic Pain",[64],"photobiomodulation; laser therapy; MLS laser; Ehlers-Danlos syndrome; chronic pain; fatigue; quality of life; observational study; pilot study","2026-06-11",{"date":67,"type":37},"2026-06-15",{"date":69,"type":37},"2026-05-26",{"date":71,"type":21},"2027-09-30",{"name":73,"class":44},"Centre Medical ISM (Integrative Systemic Medicine)",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":74},"100630718","is-post-exertional-symptom-exacerbation-specific-to-patients-with-myalgic-encephalomyelitis--chronic-fatigue-syndrome-a-study-comparing-patients-with-myalgic-encephalomyelitis--chronic-fatigue-syndrome-and-patients-with-cardiac-diseases-who-underwent-an-exercise-test-100630718","NCT07491315","Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome? A Study Comparing Patients With Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome and Patients With Cardiac Diseases Who Underwent an Exercise Test.","MAPEMCAR","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* For patients with Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome (ME\u002FCFS): Clinical diagnosis of Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome according to the International Consensus Criteria (ICC) 2011.\n* For patients with cardiac diseases : patients referred for an exercise test in the cardiology department for one of the following indications: palpitations, hypertension, exertional dyspnea, chest pain, cornoray artery disease and presence of moderate to severe fatigue defined as a Numerical Rating Scale (NRS) \\> 3\u002F10 during the last 8 days and no diagnosis of Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome.\n* Ability to use a computer or digital device required to complete online questionnaires.\n* Having given free and informed written consent\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Persons deprived of their liberty by a judicial or administrative decision.\n* Persons who are subject to a legal protection measure or who are unable to express their consent.",{"count":83,"type":21},80,[85],"NA","Myalgic Encephalomyelitis \u002F Chronic Fatigue Syndrome (ME\u002FCFS) is a disease characterized by persistent and unexplained fatigue associated with diffuse pain, sleep disorders, neurocognitive and autonomic symptoms, musculoskeletal manifestations and digestive symptoms. A central feature of this disease is post-exertional symptom exacerbation, also referred to as post-exertional malaise, defined as the worsening or the appearance of symptoms after physical or mental exertion, sometimes even minimal.\n\nSeveral studies have described post-exertional malaise in populations of patients with ME\u002FCFS following a standardized exercise test performed over one or two consecutive days. These studies confirmed the presence of post-exertional malaise in ME\u002FCFS patients compared with healthy controls or patients with multiple sclerosis.\n\nHowever, no data are available evaluating the impact of an exercise test on symptoms in patients referred to cardiology for this examination. Patients with cardiac diseases may also present symptoms such as fatigue, dyspnea or exercise intolerance.\n\nThis study aims to compare post-exertional symptoms in two populations: patients with ME\u002FCFS and patients with cardiac diseases undergoing an exercise test as part of routine clinical evaluation. The study also aims to measure variations in muscle oxyhemoglobin and deoxyhemoglobin concentrations before, during and after exercise using Near Infrared Spectroscopy (NIRS).",[28,88],"Cardiovascular Diseases","2026-06-04",{"date":91,"type":37},"2026-06-08",{"date":93,"type":37},"2025-06-24",{"date":95,"type":21},"2026-12-24",{"name":97,"class":44},"Hôpital Européen Marseille",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":74},"100552402","early-phase-1-functional-neuroimaging-to-detect-the-neural-signatures-of-the-unpleasantness-of-pain-and-effort-100552402","NCT06472622","Functional Neuroimaging to Detect the Neural Signatures of the Unpleasantness of Pain and Effort","* INCLUSION CRITERIA:\n\nHealthy Controls: In order to be eligible to participate in this study as a healthy control, an individual must meet all the following criteria:\n\n1. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged 18-50 (inclusive).\n4. Good general health as evidenced by medical history and\u002For physical examination.\n\nME\u002FCFS Patients: In order to be eligible to participate in this study as an ME\u002FCFS patient, an individual must meet all the following criteria:\n\n1. Ability of subject to understand and the willingness to sign a written informed consent document.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Male or female, aged 18-50 (inclusive).\n4. Has a diagnosis of ME\u002FCFS, meeting at least one of three ME\u002FCFS criteria: the 1994 Fukuda Criteria, the 2003 Canadian Consensus Criteria for Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome, or the Institute of Medicine Diagnostic Criteria.\n\nEXCLUSION CRITERIA:\n\nHealthy Controls:\n\n1. Any current major neurological or psychiatric disorder such as (but not limited to) stroke, Parkinson s disease, Alzheimer s disease, schizophrenia, or major depressive disorder.\n2. Any other current major medical disorder, such as a kidney disease, liver disease, cardiovascular disease, chronic pain condition, or any other disorder which, in the opinion of the PI would make participation risky for the individual or negatively affect the individual s ability to cooperate with study procedures.\n3. Current use of medications acting primarily on the central nervous system, such as antidepressants, stimulants, etc.\n4. Use of opioid medications for more than two weeks within the last two years or any use in the last month.\n5. Current or history of substance use disorder, binge drinking, illegal drug use, or excessive tobacco use (defined as more than 10 cigarettes of nicotine per week).\n6. Any more than occasional use of cannabis, defined as a score \\>1 (indicating use on more than one or two days in the last two weeks) on the marijuana use item of the DSM-5 Level 2-Substance Use-Adult questionnaire.\n7. Any use of other illicit drugs or misuse of prescription medications, defined as a score \\>0 on any of the other items of the DSM-5 Level 2-Substance Use-Adult questionnaire.\n8. Condition or injury affecting grip.\n9. Condition or injury affecting extremities that would alter peripheral sensitivity to painful thermal stimuli or would otherwise cause such stimuli to be contraindicated.\n10. Contraindications to MRI, including ferromagnetic metal in the cranial cavity or eye, implanted neural stimulator, cochlear implant, or ocular foreign body, implanted cardiac pacemaker, auto-defibrillator, or pump, non-removable body piercing, claustrophobia, inability to lie supine for 90 minutes, known pregnancy, or plans to become pregnant during the study.\n11. Members of the NINDS BNU and their family members.\n12. Non-English speakers will be excluded from the study as several study instruments do not have validated translations.\n\nME\u002FCFS Patients:\n\n1. Any current major neurological or psychiatric disorder, other than ME\u002FCFS, such as (but not limited to) stroke, Parkinson s disease, Alzheimer s disease, schizophrenia, or major depressive disorder.\n2. Any other current major medical disorder, other than ME\u002FCFS, such as a kidney disease, liver disease, cardiovascular disease, chronic pain condition, or any other disorder which, in the opinion of the PI would make participation risky for the individual or negatively\n\n   affect the individual s ability to cooperate with study procedures.\n3. Current use of psychomotor stimulants, antipsychotics, or benzodiazepines.\n4. Use of opioid medications for more than two weeks within the last two years or any use in the last month.\n5. Current or history of substance use disorder, binge drinking, illegal drug use, or excessive tobacco use (defined as more than 10 cigarettes of nicotine per week).\n6. Any more than occasional use of cannabis, defined as a score \\>1 (indicating use on more than one or two days in the last two weeks) on the marijuana use item of the DSM-5 Level 2-Substance Use-Adult questionnaire.\n7. Any use of other illicit drugs or misuse of prescription medications, defined as a score \\>0 on any of the other items of the DSM-5 Level 2-Substance Use-Adult questionnaire.\n8. Condition or injury affecting grip.\n9. Condition or injury affecting extremities that would alter peripheral sensitivity to painful thermal stimuli or would otherwise cause such stimuli to be contraindicated.\n10. Contraindications to MRI, including ferromagnetic metal in the cranial cavity or eye, implanted neural stimulator, cochlear implant, or ocular foreign body, implanted cardiac pacemaker, auto-defibrillator, or pump, non-removable body piercing, claustrophobia, inability to lie supine for 90 minutes, known pregnancy, or plans to become pregnant during the study.\n11. Members of the NINDS BNU and their family members.\n12. Non-English speakers will be excluded from the study as several study instruments do not have validated translations.","50 Years",{"count":106,"type":21},47,[108],"EARLY_PHASE1","Background:\n\nThe way the brain processes rewards and punishments may play a role in some disorders of the nervous system. People with chronic overlapping pain conditions (such as myalgic encephalomyelitis\u002Fchronic fatigue syndrome \\[ME\u002FCFS\\]) may have heightened responses to unpleasant, punishing sensations. Some of these conditions may also cause heightened responses to effort; this is an unpleasant sensation felt during physical and mental exertion.\n\nObjective:\n\nTo learn more about how the brain processes different unpleasant sensations.\n\nEligibility:\n\nPeople aged 18 to 50 years with ME\u002FCFS. Healthy volunteers are also needed.\n\nDesign:\n\nParticipants will have 3 visits in 1 to 5 weeks.\n\nVisit 1: Participants may have a neurologic exam. They will have a mock magnetic resonance imaging (MRI) scan. They will lie on a bed in a wooden tube while they practice 2 tasks:\n\nThermal pain rating: A device that creates mild to moderate heat will be placed on one leg.\n\nPhysical effort rating: Participants will squeeze a plastic bar with different levels of force.\n\nVisit 2: Participants will have a real MRI scan. They will lie on a table that slides into a large tube.\n\nVisit 3: Participants will have another MRI scan. They will repeat the thermal pain and physical effort tasks while in the scanner. Sensors will be placed on 1 arm to measure how the muscles function as they squeeze the bar.\n\nTheir heart rate will be tested: They will hold their finger against a camera lens for 1 minute. They will do 2 other tasks: 1 requires repeatedly pressing a key on a keyboard, and the other requires squeezing a bar.",[28],[112,28,113,114,115,116,117,118,119,120],"Punishment","Pain","Physical Exertion","Effort","Brain","Magnetic Resonance Imaging","Neuroimaging","Psychophysics","Reward","2026-05-12",{"date":123,"type":37},"2026-05-13",{"date":125,"type":37},"2025-04-09",{"date":127,"type":21},"2034-06-30",{"name":129,"class":130},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":149,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":74},"100522430","improving-post-covid-19-syndrome-with-hyperbaric-oxygen-treatments-100522430","NCT06082518","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments","Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments (PCS-HBOT Study)","PCS-HBOT","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Officially diagnosed with post COVID-19 condition by a healthcare practitioner\n3. At least three months since SARS-CoV-2 infection\n4. Symptoms that persist more than 12 weeks:\n\n   * Chronic fatigue (must include) along with one of the following symptoms:\n   * Difficulty thinking or problem solving ('brain fog')\n   * Stress or anxiety\n\nExclusion Criteria:\n\n1. Contraindications\u002Fmedically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)\n2. Patients with cognitive difficulties and\u002For mental retardation before COVID diagnosis\n3. History of traumatic brain injury\n4. Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)\n5. Known pregnancy or planning a pregnancy in women of childbearing age",{"count":140,"type":21},40,[85],"Over 500 million people have been infected with COVID-19, and to date, more than 6 million people have died. Many individuals who have recovered from COVID-19 continue to experience symptoms even after they have been \"cured\" of the disease. This condition is known as post COVID-19 condition, which can have serious health consequences. A common symptom among these individuals is chronic fatigue, characterized by persistent tiredness or lack of energy. This study aims to explore a novel treatment for symptoms of post COVID-19 condition, known as hyperbaric oxygen therapy. This approach has shown promise in helping people with post COVID-19 conditions and treating some other causes of fatigue.\n\nHyperbaric oxygen therapy involves placing patients in a small chamber where they receive high oxygen gas levels. However, this treatment is expensive and time-consuming, and it is unclear if this treatment can be effectively assessed in a large-scale research study. This small study will help us decide if conducting a large research study is feasible. The investigators aim to assess if hyperbaric oxygen therapy can improve symptoms of post COVID-19 condition, such as fatigue.",[144,145,146,147,148,28],"Post COVID-19 Condition","Post-COVID-19 Syndrome","Post-COVID Syndrome","COVID-19","Fatigue",[150,151,144,148,152,147],"Hyperbaric Oxygen Therapy","HBOT","Severe Acute Respiratory Syndrome-CoV-2","2026-03-12",{"date":155,"type":37},"2026-03-16",{"date":157,"type":37},"2024-01-02",{"date":159,"type":21},"2027-05",{"name":161,"class":44},"Sunnybrook Health Sciences Centre",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":169,"sex":54,"minAge":17,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":173,"conditions":174,"keywords":180,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":45},"100625773","cognitive-performance-sleep-disturbances-and-fatigue-in-multiple-sclerosis-100625773","NCT07426991","Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis","The Effects of Sleep Disturbances on Fatigue and Cognition in Multiple Sclerosis","Inclusion Criteria:\n\n* Age ≥ 18 and ≤ 79 years (all groups)\n* Adequate (corrected) hearing and vision to complete neuropsychological testing (all groups)\n* Sufficient proficiency in German to participate in assessments (all groups)\n* Capacity to provide informed consent and understanding of study procedures (all groups)\n* Diagnosis of MS according to the 2017 revised McDonald criteria (MS group)\n* Indication for sleep medicine evaluation due to at least mild fatigue, operationalized as ≥ 43 points on the Fatigue Scale for Motor and Cognitive Functions (FSMC) (MS group)\n* Indication for sleep medicine evaluation (control group)\n\nExclusion Criteria:\n\n* Lack of signed informed consent or inability to provide consent (all groups)\n* Age \\\u003C 18 years or \\> 79 years (all groups)\n* Presence of another neurological disorder in addition to MS, with the exception of migraine (all groups)\n* Use of medications that influence polysomnographic parameters (e.g., benzodiazepines) (all groups)\n* Uncorrected hearing or vision impairment and\u002For insufficient German language proficiency likely to impact neuropsychological test results (all groups)",true,"79 Years",{"count":172,"type":21},837,"Fatigue is a prevalent symptom in patients with multiple sclerosis (MS) and is associated with considerable impairment in quality of life as well as loss of occupational capacity. Sleep disturbances are regarded as a critical factor in the development of fatigue and are frequently observed in individuals with MS. However, they often remain underrecognized, undiagnosed, and consequently untreated.\n\nPolysomnography, the gold standard for assessing sleep architecture and quality, has rarely been applied in the investigation of sleep disorders in MS. Accordingly, uncertainties remain regarding the prevalence and extent to which sleep disturbances contribute to fatigue in this population. Moreover, emerging evidence suggests an association between sleep disorders and cognitive dysfunction in MS. Yet, it is unclear whether cognitive impairment arises from the sleep disorder itself, from the resulting fatigue, or from other independent factors.\n\nPharmacological treatments for MS-related fatigue remain limited, given heterogeneous and frequently non-replicable effects. Non-pharmacological interventions such as physical activity, cognitive behavioral therapy, and psychoeducation have shown promise but yield variable outcomes. The development of novel and effective therapeutic strategies requires a more comprehensive understanding of the etiology of fatigue. To date, the role of sleep disturbances and their relationship to cognitive performance in MS have not been adequately investigated.\n\nThe objective of this project is to determine the prevalence and characteristics of sleep disorders in MS patients with fatigue using polysomnography and to examine their relationship with cognitive impairment. In addition, the study will compare sleep quality parameters and the prevalence of sleep disorders across different MS subtypes (relapsing-remitting, primary progressive, and secondary progressive). Furthermore, within a sub-study, it will be investigated whether the type of immunotherapy has an influence on the aforementioned aspects.\n\nFinally, the project seeks to integrate artificial intelligence (AI) into polysomnography analysis to streamline data evaluation and facilitate the future assessment of therapeutic interventions.\n\nThe study will be conducted as a non-invasive, non-interventional, longitudinal observational trial including MS patients with fatigue and a control group of patients with subjective sleep complaints but without MS. Recruitment will take place over 36 months at two centers: the Department of Neurology at the University Hospital Düsseldorf and the Maria Hilf Clinics in Mönchengladbach. Additional recruitment will be supported by community-based neurologists in the Mönchengladbach region to broaden the study cohort and ensure representativeness of the study population.\n\nApproximately 382 MS patients are expected to be enrolled. The number of control participants will be determined by the proportion of MS patients presenting with sleep disorders and will be recruited consecutively from the neurological sleep laboratory of the Maria Hilf Clinics. For AI training, retrospective polysomnography data from the past five years (N ≥ 10,000 patients) at the Maria Hilf Clinics will be utilized.\n\nThe study protocol includes overnight polysomnography to assess sleep quality, along with comprehensive clinical evaluation, neuropsychological testing, and validated questionnaires addressing fatigue, subjective sleep quality, daytime sleepiness, depression, and anxiety.\n\nBased on manually scored polysomnography, AI models will be trained to identify key parameters of sleep quality. The findings of this study will advance the understanding of the role of sleep disturbances in MS-related fatigue and will facilitate the integration of AI into sleep research, thereby streamlining the evaluation of future therapeutic approaches.",[175,176,177,178,28,179],"Multiple Sclerosis","Remitting-Relapsing Multiple Sclerosis","Primary Progressive Multiple Sclerosis","Secondary Progress Multiple Sclerosis","Sleep Disorders",[181,182,148,183],"MS","Sleep","Cognition","2026-03-05",{"date":186,"type":37},"2026-03-06",{"date":188,"type":37},"2024-11-01",{"date":190,"type":21},"2028-12",{"name":192,"class":44},"Heinrich-Heine University, Duesseldorf",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":201,"minAge":17,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":22,"phases":204,"briefSummary":205,"conditions":206,"keywords":211,"overallStatus":223,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100624462","multicomponent-care-for-aromatase-inhibitor-related-musculoskeletal-symptoms-100624462","NCT07409948","Multicomponent Care for Aromatase Inhibitor-Related Musculoskeletal Symptoms","Clinical Effectiveness and Implementation Outcomes of a Multicomponent Intervention for Aromatase Inhibitor-Associated Musculoskeletal Symptoms: A Hybrid Type 1 Randomized Controlled Trial","AIMSS-CARE","Inclusion Criteria:\n\n1. Pathologically confirmed hormone receptor-positive (HR+) breast cancer.\n2. Aged 18 years or older.\n3. Currently receiving aromatase inhibitor therapy (e.g., anastrozole, letrozole, or exemestane) for at least 2 months.\n4. Experiencing aromatase inhibitor-induced musculoskeletal symptoms, defined as a worst joint pain score ≥ 2\u002F10 on the Brief Pain Inventory (BPI) during the past 7 days.\n5. Capable of understanding the study and willing to sign informed consent.\n\nExclusion Criteria:\n\n1. History of fracture or major surgery within the past 6 months.\n2. Patients diagnosed with arthritis (e.g., rheumatoid arthritis).\n3. Patients diagnosed with osteoporosis according to WHO criteria (T-score -2.5).\n4. Recurrent or metastatic breast cancer, or receipt of chemotherapy or radiotherapy during the study period.\n5. Presence of other primary malignancies.\n6. Patients with severe heart, brain, liver, or kidney dysfunction, or infectious diseases.\n7. Patients with severe mental, cognitive, or behavioral disorders that hinder understanding or participation in the study.","FEMALE",{"count":203,"type":21},88,[85],"Breast cancer patients who receive endocrine therapy particularly aromatase inhibitors often experience aromatase inhibitors associated symptoms (AIMSS) such as joint and muscle pain along with stiffness and fatigue that can disrupt with daily activities and lead some patients to stop treatment early. A structured intervention program named AIMSS-CARE (Aromatase Inhibitor-associated Musculoskeletal Symptoms-Comprehensive Adapted Rehabilitation Evaluation) developed in China that combines exercise, education, symptom monitoring, and follow-up has been shown to reduce these symptoms and improve treatment adherence.\n\nThis study will adapt this program for use in Ethiopia while testing its effectiveness to enhance pain management, treatment adherence and quality of life among Ethiopian breast cancer patients receiving endocrine therapy. The study will be conducted at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia.\n\nEighty-eight patients will be randomly assigned to either the adapted intervention program or usual care. The research will also examine the feasibility and acceptability of the intervention to patients and healthcare providers, and what factors influence its successful implementation. Results will help determine whether this program can be used more widely in Ethiopia and other African cancer centers.",[207,208,209,210,113,28],"Breast Neoplasms","Musculoskeletal Pain","Arthralgia","Musculoskeletal Diseases",[212,213,214,215,216,217,218,219,220,221,222],"Breast neoplasms","Aromatase inhibitors","endocrine therapy","Randomized controlled trial","pain","quality of life","fatigue","treatment adherence","musculoskeletal symptoms","symptom monitoring","exercise and rehabilitation","NOT_YET_RECRUITING","2026-02-07",{"date":226,"type":37},"2026-02-13",{"date":228,"type":21},"2026-03-15",{"date":230,"type":21},"2026-11",{"name":232,"class":44},"Addis Ababa University",{"id":234,"slug":235,"hasResults":11,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":223,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":4},"100545763","chronic-fatigue-in-multiple-sclerosis-ms-copilot-boost-solution-compared-to-standard-care-100545763","NCT06386133","Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care","Chronic Fatigue in Multiple Sclerosis: Validating Clinical Performance, Economic, and Organizational Benefits of MSCopilot Boost Compared to Standard Care","MSBoost","Inclusion Criteria:\n\n* Aged over 18 years\n* With a confirmed MS diagnosis according to 2017 McDonald's revised criteria\n* Having an EDSS score comprised between 0 and 6.5\n* With a fatigue score ≥ 43 on MFIS scale\n* Able to walk with or with walking aids\n* Owning a personal smartphone with a mobile operating system version higher than 14 for IOS (iPhone) and 8 for Android\n* Able to read the language in which the mobile application is available and able to understand pictograms\n* Affiliated to a social security system\n* Having signed the free and informed consent\n* Having accepted to wear an actimeter during the whole duration of study participation\n* Having been on a stable disease-modifying therapy for MS for at least 6 months.\n\nExclusion Criteria:\n\n* Psychiatric disorder, major visual or cognitive deficiency, as assessed by the investigator\n* Participation in an exercise reconditioning program at a rehabilitation center within the 6 weeks prior to inclusion\n* Major comorbidities that could influence fatigue management (lupus, rheumatoid arthritis, chronic obstructive pulmonary disease, chronic fatigue syndrome, etc).\n* Contraindication to physical activity:\n* History of cardiac events:\n* Abnormal cardiac examination at last medical check-up.\n* Palpitations, tachycardia or irregular heartbeat\n* Pain and shortness of breath:\n* Cramp-like pain in the lower limbs when walking, disappearing when walking stops, except for MS-related pain (neuropathic or spastic).\n* Chest pain\n* Shortness of breath at rest (appearing or worsening in the lying position)\n* Shortness of breath during low-intensity exercise or usual activities\n* Pain, discomfort or heaviness in the chest at rest or during exertion\n* Unstable chronic diseases :\n* Unstable metabolic disease\n* Unstable renal disease\n* Uncontrolled chronic disease\n* Ankle edema\n* Dizziness or syncope\n* Having received fampridine, corticosteroid therapy or therapeutic cannabis within the 2 months prior to inclusion.\n* Psychoactive substances and\u002For alcohol consumption likely to influence test performance (investigator's judgment).\n* Patients confined to bed or whose daily activity is less than 2 hours.\n* Persons under guardianship or curatorship.\n* Pregnant or breast-feeding women.\n* Subjects who have participated in another clinical study within 30 days prior to selection, or who are participating in another study that, in the opinion of the investigator, could interfere with full participation in the study or confound the participant's assessment or the study results.",{"count":242,"type":21},208,[85],"The main objective of the MS Boost study is to demonstrate the superiority of MSCopilot Boost over standard practice in reducing the impact of fatigue on Patients with Multiple Sclerosis (MS).\n\nThe secondary objectives include validating MSCopilot Boost clinical performance in reducing fatigue and its impact as well as evaluating its functional tests performance and its safety of use. The investigation team will also investigate the effects of MSCopilot Boost on patient symptoms, functional parameters and physical activity levels. The investigation team will evaluate patients and healthcare professionals' perceived clinical benefit as well as adherence, satisfaction and user experience related to the mobile application and the web portal. Ultimately, the investigation team will define the medico-economic and organizational impact of the MSCopilot Boost solution.\n\nPatients' expected benefits are the access to additional clinical tests not routinely performed, covering dimensions not addressed by standard tests like the EDSS for example; a remote monitoring of functional tests similar to those of the modified MSFC with the possibility of adding an evaluation of fatigue through digital questionnaires; improvement of symptoms related to MS fatigue through access to a personalised tele-rehabilitation program.\n\nHealthcare professionals' expected benefits are to track objective measures of key functional symptoms of the disease between consultations, supporting MS patients' management and to gain time by providing a \"big picture\" of the patient's condition over time.",[175,28],[247,248,249,250],"Mobile application","Digital monitoring","Fatigue management","Multiple sclerosis","2025-09-30",{"date":253,"type":37},"2025-10-03",{"date":255,"type":21},"2026-12-01",{"date":257,"type":21},"2027-08-01",{"name":259,"class":44},"Ad scientiam",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":169,"sex":54,"minAge":17,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":22,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":74},"100345077","research-for-pathophysiology-of-cancer-related-fatigue-crf-and-chronic-fatigue-cfsme-100345077","NCT03773003","Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS\u002FME)","Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS\u002FME) by Lipidomics, Metabolomics, Microbiome and Exome Analysis and Investigation of Clinical Improvement Under Administration of Probiotics","IMPROFA","Inclusion Criteria:\n\n* histologically, cytologically or radiologically confirmed tumor disease\n* indication for chemotherapy\n* Written consent to participation\n\nExclusion Criteria:\n\n* chronic-inflammatory bowel disease\n* pregnancy","80 Years",{"count":270,"type":21},150,[85],"Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue Syndrome (CFS\u002FME) by Lipidomics, Metabolomics, Intestinal and Peritoneal Microbiome Analysis and Exome Analysis and Investigation of a Possible Benefit of Probiotics.",[274,28],"Cancer Related Fatigue",[276],"Cancer Fatigue, Chronic Fatigue","2025-05-22",{"date":279,"type":37},"2025-05-29",{"date":281,"type":37},"2021-07-20",{"date":283,"type":21},"2025-12-01",{"name":285,"class":44},"Universität des Saarlandes",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":295,"conditions":296,"keywords":297,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":74},"100337564","assessment-of-exercise-response-in-chronic-fatigue-syndrome--myalgic-encephalomyelitis-100337564","NCT03675087","Assessment of Exercise Response in Chronic Fatigue Syndrome \u002F Myalgic Encephalomyelitis.","Inclusion Criteria:\n\n* To be diagnosed by a medical specialist in internal medicine with experience in this disease. For this, the participant must fulfill with the diagnostic criteria of CFS\u002FME, following the recommended criteria for the diagnosis of 2015.\n* Prior signing of the informed consent.\n\nExclusion Criteria:\n\n* Present any of the diagnoses considered excluding of the CFS\u002FME, according to the international criteria recommended for clinical diagnosis and the selection of subjects for research:\n\n  * Primary psychiatric disorders\n  * Somatoform disorders\n  * or Substance abuse\n* Present any of the absolute or relative contraindications, to perform exercise tests, described in previous investigations:\n\n  * Decompensated heart failure\n  * Acute myocardial infarction (less than 3 days)\n  * Syncope\n  * Unstable angina\n  * Cardiac arrhythmia poorly controlled\n  * Endocarditis, myocarditis or acute pericarditis\n  * Acute pulmonary edema\n  * Moderate or severe cardiac valvular stenosis\n  * Suspected dissection or dissecting aortic aneurysm\n  * O2 saturation at rest less than 85%\n  * Acute renal failure\n  * Untreated thyrotoxicosis\n  * Acute infection\n  * Uncontrolled hypertension (greater than 200-120 mmHg)\n  * Hypertrophic obstructive cardiomyopathy\n  * High-grade atrioventricular block\n  * Significant pulmonary arterial hypertension\n  * Advanced or risky pregnancy\n  * Significant diselectrolithmia\n  * Severe symptomatic aortic stenosis\n  * Severe anemia\n  * Pulmonary embolism\n  * Acute thrombophlebitis\n  * Traumatologic, orthopedic or neurological pathology that does not allow to walk or cycling.\n  * Psychic incapacity to understand the instructions of the tests.\n  * Present comorbidity of Multiple Chemical Sensitivity Syndrome.\n  * Have performed the peak incremental CPET in the last 3 years.","65 Years",{"count":294,"type":21},22,"This study evaluates the correlation between the 6-min walking test (6MWT) with gases measurement, and the peak cardiopulmonary exercise testing (CPET) using incremental cycling with gases and workload measurement, in order to determine if the 6MWT detects impairment in exercise tolerance and if it avoids the post-exertional malaise that the peak CPET causes on decreasing levels of physical activity, in participants affected by chronic fatigue syndrome\u002F myalgic encephalomyelitis (CFS\u002FME).\n\nPhysical activity level at baseline (usual activity, the parcipant will not be given any directions) will be recorded during 7 days, 24 hours\u002Fday. Afterwards, the 6MWT will be performed. After this test, the physical activity level will be collected again during 7 days, 24 hours\u002Fday. Peak CPET will be carried out 14 days after 6MWT to make sure that the basal levels are recovered, and finally, physical activity level will be collected again during 7 days, 24 hours\u002Fday.",[28],[298,299,300],"Work Capacity Evaluation","Fatigue Syndrome,Chronic","Exercise Tests","2025-03-07",{"date":303,"type":37},"2025-03-10",{"date":305,"type":37},"2019-02-27",{"date":307,"type":21},"2025-12",{"name":309,"class":44},"Escuela Universitaria de Fisioterapia de la Once",{"id":311,"slug":312,"hasResults":11,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":319,"conditions":320,"keywords":322,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":74},"100575667","chronic-fatigue-in-the-internal-medicine-outpatient-clinic-a-mixed-methods-quantitative-and-qualitative-study-100575667","NCT06775262","Chronic Fatigue in the Internal Medicine Outpatient Clinic: a Mixed-methods Quantitative and Qualitative Study","Patients with Chronic Fatigue Complaints for Whom a Consultation Including Diagnostics Do Not Reveal a Somatic Diagnosis Atthe Internal Medicine Outpatient Clinic","Cohort 1:\n\nInclusion Criteria:\n\n* Patients under 18 years of age;\n* Patients lost to follow-up.\n\nExclusion Criteria:\n\n* Patients at the internal medicine outpatient clinic with a referral for fatigue e.c.i.\n* Patients who visited the clinic after the 1st of April 2022.\n\nCohort 2:\n\nInclusion criteria\n\n* Patients at the internal medicine outpatient clinic with a referral for fatigue e.c.i. whose consultation did not bring about a somatic diagnosis\n\nExclusion criteria:\n\n* Patients under 18 years of age;\n* Patients that do not speak Dutch fluently",{"count":318,"type":21},100,"With this study, the investigators aim to answer the following research questions:\n\n1. In what percentage of cases does the diagnostic process conducted during a fatigue consultation at the internal medicine outpatient clinic contribute to a somatic diagnosis?\n2. What are the experiences of patients presenting with fatigue at the internal medicine outpatient clinic when a consultation, including diagnostic testing, does not lead to a diagnosis?\n\nTo address question (1), the investigators will conduct a retrospective data analysis using information from HiX, an electronic health record (EHR) system.\n\nTo answer question (2), the investigators will conduct a prospective qualitative study through interviews.",[321,148,28],"Fatigue Symptom",[148,323,324,325,326,327,328],"Qualitative study","Quantative study","Diagnostic efficacy","Internal medicine","Interviews","Grounded theory","2025-02-25",{"date":331,"type":37},"2025-02-27",{"date":333,"type":37},"2024-12-20",{"date":335,"type":21},"2025-07-25",{"name":337,"class":44},"Flevoziekenhuis",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":54,"minAge":17,"maxAge":345,"enrollmentInfo":346,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":349,"conditions":350,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":74},"100452178","effectiveness-of-acceptance-commitment-therapy-or-micro-breaks-in-patients-with-chronic-fatigue-syndrome-myalgic-encephalomyelitis-100452178","NCT05168124","Effectiveness of Acceptance Commitment Therapy or Micro Breaks in Patients with Chronic Fatigue Syndrome\u002F Myalgic Encephalomyelitis","Study to Determine the Effectiveness of Therapy Methods (acceptance Commitment Therapy, Micro Breaks) in Patients with Chronic Fatigue Syndrome\u002F Myalgic Encephalomyelitis","Inclusion Criteria:\n\n* Diagnosis for CFS\u002FME\n* Psychiatric clinical stability in the past 3 months:\n* No diagnostic change to other categories of the International Classification of Diseases (ICD-10)\n* No psychiatric inpatient treatments\n* No psychiatric emergency treatments\n* No suicide attempts\n* Possession of internet access\n* Sufficient skills to use electronic devices\n* The willingness to engage in the described therapeutic procedures or interventions (ACT, MBEL)\n\nExclusion Criteria:\n\n* Insufficient knowledge of German\n* Severe psychiatric disorders (e.g. personality and posttraumatic stress disorders, dissociative and psychotic disorders, intelligence reduction, untreated attention deficit hyperactivity disorder) and acute suicidal tendencies\n* Untreated or severe internal medicine disorders e.g., thyroid dysfunction, central and obstructive sleep apnea syndrome (i.e., apnea-hypopnea index \\>15 and\u002For \"high-risk group for obstructive sleep apnea\" according to the Berlin Questionnaire)\n* Cardiovascular disease such as chronic heart failure\n* Severe or untreated neurological diseases (e.g. Parkinson's disease, dementia, restless legs syndrome, narcolepsy)\n* Alcohol and drug dependence\n* Initiation of psychopharmacotherapy at a dosage provided for guideline-appropriate treatment of a mental disorder according to the Drug Compendium in the past 3 months\n* Start of other psychotherapy procedures in the last 3 months\n* Other parallel therapy methods (e.g. acupuncture, qigong, osteopathy)\n* Somatic (sleep-disrupting) treatments, cortisone treatment, or radio-\u002Fchemotherapy in the last 6 months","55 Years",{"count":347,"type":21},90,[85],"Chronic fatigue syndrome\u002Fmyalgic encephalomyelitis (CFS\u002FME) is a distinct disease entity with an estimated prevalence of 0.3-0.7% and more common in women (3:1 ratio). It can be diagnosed according to the Institute of Medicine (IOM) 2015 consensus definition using 3 major criteria and one of 2 minor criteria.\n\nDiagnosis requires that the patient have the following three symptoms:\n\n1. A substantial reduction or impairment in the ability to engage in pre-illness levels of occupational, educational, social, or personal activities that persists for more than 6 months and is accompanied by fatigue, which is often profound, is of new or definite onset (not lifelong), is not the result of ongoing excessive exertion, and is not substantially alleviated by rest,\n2. Post-exertional malaise,\\* and\n3. Unrefreshing sleep\\*\n\nAt least one of the two following manifestations is also required:\n\n1. Cognitive impairment\\* or\n2. Orthostatic intolerance\n\nNote\\* Frequency and severity of symptoms should be assessed. The diagnosis of ME\u002FCFS should be questioned if patients do not have these symptoms at least half of the time with moderate, substantial, or severe intensity.\n\nCurrently, individually tailored therapy with emphasis on cognitive behavioral therapy and graduated activity therapy is considered the therapy of first choice, although their effectiveness has been critically questioned in recent years. There are often frustrating treatment courses, a larger proportion of partial remissions, a significantly smaller proportion of full remissions and return to work.\n\nThe study aims to evaluate patients of the outpatient service for chronic fatigue at the Department of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Switzerland, in the context of a group therapy for the treatment of CFS\u002FME in respect to the response to different, non-drug based therapeutic procedures and to gain knowledge about the effects of the therapy.\n\nThe study is a clinical comparative study of therapeutic procedures\u002Finterventions without the use of drugs or a medical product. The interventions are Acceptance Commitment Therapy (ACT) and Micro Breaks in Everyday Life (MBEL) adapted to CFS\u002FME. The collection of biological samples (saliva, blood) and health-related personal data (actigraphy, psychometric data from questionnaires) is associated with minimal risks and burdens.",[28],"2024-12-10",{"date":353,"type":37},"2024-12-16",{"date":355,"type":37},"2023-08-08",{"date":357,"type":21},"2026-07",{"name":359,"class":44},"Sarah Schiebler"]